Kamada

Kamada Added to the NASDAQ Biotechnology Index

Retrieved on: 
Monday, December 21, 2020
Finance, NASDAQ, Financial markets, Exchange-traded funds, NASDAQ Biotechnology Index, Money, Tel Aviv Stock Exchange, iShares, Kamada, TA BlueTech Index

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(Nasdaq: NBI).

Key Points: 
  • REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(Nasdaq: NBI).
  • The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020.
  • The NASDAQ Biotechnology Index (NBI) is a modified market-cap weighted index designed to track the performance of a set of securities listed on the NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.
  • Additionally, the NBI forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF (Nasdaq: IBB).

Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020

Retrieved on: 
Wednesday, November 4, 2020
Kamada, Rehovot, Science and technology in Israel, Tel Aviv Stock Exchange, Companies, Conference call, Tase, NASDAQ, Economy of the Middle East, Finance

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets on Wednesday, November 11, 2020.

Key Points: 
  • REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the third quarter ended September 30, 2020, prior to the open of the U.S. financial markets on Wednesday, November 11, 2020.
  • Kamada management will host an investment community conference call on Wednesday, November 11, at 8:30am Eastern Time to discuss these results and answer questions.
  • Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13710863.
  • The call will also be webcast live on the Internet on the Companys website at www.kamada.com .

Kedrion Biopharma's Chairman, Paolo Marcucci, has been awarded with the 2020 Otto Schwarz Award at PPTA's Global Plasma Summit

Retrieved on: 
Tuesday, November 3, 2020
Life sciences, Biotechnology, Articles, Kamada, Rehovot, Science and technology in Israel, Biopharmaceutical, Marcucci

LUCCA, Italy, Nov. 3, 2020 /PRNewswire/ --Paolo Marcucci, Chairman of Kedrion Biopharma, a major international biopharmaceutical company and leader in the field of plasma-derived therapies, has received the Otto Schwarz Award on the final day of the PPTA's Global Plasma Summit 2020.

Key Points: 
  • LUCCA, Italy, Nov. 3, 2020 /PRNewswire/ --Paolo Marcucci, Chairman of Kedrion Biopharma, a major international biopharmaceutical company and leader in the field of plasma-derived therapies, has received the Otto Schwarz Award on the final day of the PPTA's Global Plasma Summit 2020.
  • The prize, one of the most prestigious international awards in this sector,recognizes worldwide leaders who, through their work and dedication, have had a disruptive impact in the plasma protein therapeutics industry.
  • As of now Kedrion, in collaboration with its Israeli partner Kamada, is continuing with the development of new anti-Covid therapies.
  • "Receiving this distinguished recognition, in this delicate historical moment we are all experiencing, is a source of great pride for me," said Paolo Marcucci at the award ceremony.

Kedrion Biopharma's Chairman, Paolo Marcucci, has been awarded with the 2020 Otto Schwarz Award at PPTA's Global Plasma Summit

Retrieved on: 
Tuesday, November 3, 2020
Life sciences, Biotechnology, Articles, Kamada, Rehovot, Science and technology in Israel, Biopharmaceutical, Marcucci

LUCCA, Italy, Nov. 3, 2020 /PRNewswire/ --Paolo Marcucci, Chairman of Kedrion Biopharma, a major international biopharmaceutical company and leader in the field of plasma-derived therapies, has received the Otto Schwarz Award on the final day of the PPTA's Global Plasma Summit 2020.

Key Points: 
  • LUCCA, Italy, Nov. 3, 2020 /PRNewswire/ --Paolo Marcucci, Chairman of Kedrion Biopharma, a major international biopharmaceutical company and leader in the field of plasma-derived therapies, has received the Otto Schwarz Award on the final day of the PPTA's Global Plasma Summit 2020.
  • The prize, one of the most prestigious international awards in this sector,recognizes worldwide leaders who, through their work and dedication, have had a disruptive impact in the plasma protein therapeutics industry.
  • As of now Kedrion, in collaboration with its Israeli partner Kamada, is continuing with the development of new anti-Covid therapies.
  • "Receiving this distinguished recognition, in this delicate historical moment we are all experiencing, is a source of great pride for me," said Paolo Marcucci at the award ceremony.

Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021

Retrieved on: 
Monday, October 19, 2020
Anatomy, Body fluids, Branches of biology, Transfusion medicine, Blood, Kamada, Rehovot, Science and technology in Israel, Management of COVID-19, Food and Drug Administration, Coronavirus disease, Blood plasma

The initial order, planned to be supplied during the beginning of 2021, is sufficient to treat approximately 500 hospitalized patients.

Key Points: 
  • The initial order, planned to be supplied during the beginning of 2021, is sufficient to treat approximately 500 hospitalized patients.
  • This initial supply is expected to generate approximately $3.4 million in revenue for Kamada during the first quarter of 2021.
  • The companies U.S. clinical development of a plasma-derived IgG product as a potential COVID-19 treatment is expected to begin in early 2021 pending IND acceptance.
  • The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA.

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

Retrieved on: 
Wednesday, October 7, 2020
Kamada, Rehovot, Science and technology in Israel, Takeda, Companies, Economy of Israel, Video games

REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, it expects to receive approximately $25 million in revenues from the supply of GLASSIA to Takeda in 2021.

Key Points: 
  • REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda, it expects to receive approximately $25 million in revenues from the supply of GLASSIA to Takeda in 2021.
  • As previously indicated, the agreement with Takeda provided a supply range for 2021 pursuant to which Kamadas revenues from sales of GLASSIA to Takeda were projected to be between $25 million to $50 million.
  • The 2021 supply range was included in the agreement to provide flexibility for Takeda to address any potential changes in the expected timeline for its completion of the planned transition of GLASSIA manufacturing.
  • As such, Takeda anticipates that its 2021 GLASSIA demand from Kamada will not exceed the minimum commitment under the supply agreement which is expected to generate $25 million of revenue for Kamada.

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment

Retrieved on: 
Tuesday, August 25, 2020
Antibodies, Antivirals, Medicine, Coronavirus disease, Occupational safety and health, Zoonoses, Clinical medicine, Kamada, Medical specialties, Coronavir, Neutralizing antibody

CASTELVECCHIO PASCOLI,Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma ofItalyand Kamada Ltd. ofIsrael- are continuing their work on the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product.

Key Points: 
  • CASTELVECCHIO PASCOLI,Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma ofItalyand Kamada Ltd. ofIsrael- are continuing their work on the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product.
  • KEDPLASMAUSA, with the approval of the Food and Drug Administration (FDA), has already begun collecting COVID-19 convalescent plasma in various collection centers in the United States.
  • The U.S. Food and Drug Administration on Sunday gave emergency approval for expanded use of antibody-rich blood plasma to help hospitalized coronavirus patients.
  • Columbia University will test the convalescent plasma against viral proteins to check the neutralizing power of the hyperimmune Immunoglobulins.

Leading Biotech Companies Kedrion Biopharma of Italy and Kamada Ltd. of Israel Continue Their Collaboration to Develop a New Anti-COVID Plasma-Based Treatment

Retrieved on: 
Tuesday, August 25, 2020
Antibodies, Antivirals, Medicine, Coronavirus disease, Occupational safety and health, Zoonoses, Clinical medicine, Kamada, Medical specialties, Coronavir, Neutralizing antibody

CASTELVECCHIO PASCOLI,Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma ofItalyand Kamada Ltd. ofIsrael- are continuing their work on the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product.

Key Points: 
  • CASTELVECCHIO PASCOLI,Italy, Aug. 25, 2020 /PRNewswire/ -- Two innovative bio-pharma companies specialized in plasma-derived therapeutics - Kedrion Biopharma ofItalyand Kamada Ltd. ofIsrael- are continuing their work on the development, manufacturing and clinical distribution of a plasma-derived Anti-SARS-CoV-2 product.
  • KEDPLASMAUSA, with the approval of the Food and Drug Administration (FDA), has already begun collecting COVID-19 convalescent plasma in various collection centers in the United States.
  • The U.S. Food and Drug Administration on Sunday gave emergency approval for expanded use of antibody-rich blood plasma to help hospitalized coronavirus patients.
  • Columbia University will test the convalescent plasma against viral proteins to check the neutralizing power of the hyperimmune Immunoglobulins.

Kamada Announces Changes to its Board of Directors

Retrieved on: 
Wednesday, August 12, 2020
Articles, Business, Kamada, Rehovot, Science and technology in Israel, Tel Aviv Stock Exchange, Board of directors, Asher, Economy

Lilach Asher Topilsky, a Director on the Companys Board and a Senior Partner at FIMI Opportunity Funds, Appointed Chairman

Key Points: 
  • Lilach Asher Topilsky, a Director on the Companys Board and a Senior Partner at FIMI Opportunity Funds, Appointed Chairman
    REHOVOT, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced changes to the composition of its Board of Directors.
  • I am honored to have been appointed as Kamadas Chairman of the Board, said Ms. Asher Topilsky.
  • I would like to thank Leon for his service as Chairman, and look forward to his continued significant contribution to the Board.
  • Commenting on Prof. Shamiss appointment, the Chairman said, I am happy to welcome Prof. Shamiss to Kamadas Board of Directors.

Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel

Retrieved on: 
Monday, August 10, 2020
Kamada, Rehovot, Science and technology in Israel, Medicine, Articles, Coronavirus disease, Health

This Phase 1/2 open-label, single-arm multi-center study was approved by the Ministry of Health in Israel.

Key Points: 
  • This Phase 1/2 open-label, single-arm multi-center study was approved by the Ministry of Health in Israel.
  • The trial will assess the safety, pharmacokinetics, and pharmacodynamics of the Companys plasma-derived IgG product in hospitalized, non-ventilated COVID-19 patients with pneumonia.
  • In parallel, Kamada intends to further explore the potential of its IgG product to prevent COVID-19 disease in healthy subjects at risk in a separate study.
  • The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA.